Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Cut to $36.00 by Analysts at HC Wainwright

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price target lowered by HC Wainwright from $40.00 to $36.00 in a research report released on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ Q1 2025 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.94) EPS, FY2026 earnings at $0.34 EPS, FY2027 earnings at $0.58 EPS, FY2028 earnings at $1.21 EPS and FY2029 earnings at $1.73 EPS.

Other research analysts also recently issued reports about the stock. Needham & Company LLC restated a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, January 13th. The Goldman Sachs Group decreased their target price on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a research note on Monday, February 10th. TD Cowen upgraded shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. Finally, Bank of America decreased their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $34.86.

Day One Biopharmaceuticals Stock Down 4.0 %

Day One Biopharmaceuticals stock opened at $9.06 on Wednesday. Day One Biopharmaceuticals has a 52-week low of $9.02 and a 52-week high of $18.07. The firm has a fifty day moving average of $12.16 and a 200-day moving average of $13.38. The firm has a market capitalization of $913.66 million, a P/E ratio of -8.80 and a beta of -1.46.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The firm had revenue of $29.21 million for the quarter, compared to the consensus estimate of $27.11 million. On average, research analysts expect that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total transaction of $399,300.00. Following the transaction, the insider now directly owns 1,034,015 shares in the company, valued at $13,762,739.65. This represents a 2.82 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel Adam Dubow sold 4,646 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the transaction, the general counsel now owns 39,602 shares in the company, valued at $473,639.92. This trade represents a 10.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 51,064 shares of company stock worth $651,225 in the last ninety days. 8.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. FMR LLC raised its holdings in shares of Day One Biopharmaceuticals by 73.9% during the fourth quarter. FMR LLC now owns 12,887,467 shares of the company’s stock worth $163,284,000 after purchasing an additional 5,475,087 shares during the period. Alyeska Investment Group L.P. acquired a new stake in shares of Day One Biopharmaceuticals during the fourth quarter worth $31,829,000. Braidwell LP raised its holdings in shares of Day One Biopharmaceuticals by 60.5% during the third quarter. Braidwell LP now owns 4,873,853 shares of the company’s stock worth $67,893,000 after purchasing an additional 1,837,949 shares during the period. Vestal Point Capital LP raised its holdings in shares of Day One Biopharmaceuticals by 100.0% during the third quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock worth $34,825,000 after purchasing an additional 1,250,000 shares during the period. Finally, Boxer Capital Management LLC acquired a new stake in shares of Day One Biopharmaceuticals during the fourth quarter worth $15,077,000. 87.95% of the stock is currently owned by institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.